Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Sativex
Sativex is an oromucosal spray containing a standardized, whole plant extract of *Cannabis sativa* L. with a defined ratio of two main cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). It is indicated for the treatment of moderate to severe spasticity due to multiple sclerosis (MS) in patients who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. Sativex acts on the cannabinoid receptors in the central nervous system, modulating neuronal activity and reducing spasticity.
Sativex is used to treat moderate to severe spasticity in multiple sclerosis patients who have not responded adequately to other anti-spasticity medications.
Outcome:
Increased sedation and impaired cognitive function
Mechanism:
Additive CNS depressant effects
Outcome:
Increased muscle relaxation and potential for falls
Mechanism:
Additive muscle relaxant effects
Outcome:
May reduce the sedative effects of Sativex
Mechanism:
Caffeine's stimulant effects
Most likely new formulation: Transdermal patch (Year: 2025, 70% confidence)
Based on clinical trial data and the current regulatory landscape, there is a moderate (50-60%) likelihood of Sativex gaining broader FDA approval for spasticity and other indications in the next 5 years.
Cannabinoid
Cannabinoid